Home » Stocks » ADMS

Adamas Pharmaceuticals, Inc. (ADMS)

Stock Price: $4.45 USD 0.00 (0.00%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $4.51 +0.06 (1.35%) Nov 27, 1:47 PM

Stock Price Chart

Key Info

Market Cap 126.92M
Revenue (ttm) 69.80M
Net Income (ttm) -62.21M
Shares Out 28.52M
EPS (ttm) -2.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $4.45
Previous Close $4.45
Change ($) 0.00
Change (%) 0.00%
Day's Open 4.37
Day's Range 4.33 - 4.55
Day's Volume 119,831
52-Week Range 1.99 - 7.30

More Stats

Market Cap 126.92M
Enterprise Value 171.18M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 28.52M
Float n/a
EPS (basic) -2.21
EPS (diluted) -2.21
FCF / Share -2.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.18M
Short Ratio 6.26
Short % of Float n/a
Beta 2.57
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.82
PB Ratio n/a
Revenue 69.80M
Operating Income -48.75M
Net Income -62.21M
Free Cash Flow -58.69M
Net Cash -44.26M
Net Cash / Share -1.55
Gross Margin 74.74%
Operating Margin -69.84%
Profit Margin -89.10%
FCF Margin -84.09%
ROA -18.69%
ROE n/a
ROIC -23.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 6
Overweight 0
Hold 2
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$9.07*
(103.82% upside)
Low
3.00
Current: $4.45
High
19.00
Target: 9.07
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue54.6434.050.570.571.9255.8571.1037.47
Revenue Growth60.48%5862.52%-0.17%-70.15%-96.57%-21.45%89.73%-
Gross Profit52.1733.410.550.571.9255.8571.1037.47
Operating Income-92.24-115-87.93-60.98-57.4418.5157.0219.95
Net Income-105-131-89.49-60.06-51.808.9733.0711.44
Shares Outstanding27.6826.8922.5621.7118.1114.849.519.49
Earnings Per Share-3.80-4.87-3.97-2.77-2.860.532.991.17
EPS Growth------82.27%155.56%-
Operating Cash Flow-80.78-104-66.83-48.07-47.2127.7926.8051.96
Capital Expenditures-0.02-1.06-1.26-1.62-1.40-1.29-0.17-0.02
Free Cash Flow-80.80-105-68.09-49.69-48.6126.5126.6351.94
Cash & Equivalents13321117311410712285.6162.96
Total Debt136119103----4.00
Net Cash / Debt-3.3891.7570.8011410712285.6158.96
Assets16223518614212916186.2264.30
Liabilities16314512010.2912.5614.1210.4640.19
Book Value-0.8989.8966.1313211614756.614.97
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adamas Pharmaceuticals, Inc.
Country United States
Employees 136
CEO Neil F. McFarlane

Stock Information

Ticker Symbol ADMS
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ADMS
IPO Date April 10, 2014

Description

Adamas Pharmaceuticals focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.